AZ
AZN
HealthcareAstraZeneca PLC
Drug Manufacturers - General
Total Trades
16
Unique Traders
6
Purchases / Sales
10/6
News Articles
5
Trading History
| Date | Politician | Asset | Action | Amount | Trade Price | 30D Price | 1M Return | Alpha | 1M Prediction |
|---|---|---|---|---|---|---|---|---|---|
Feb 13, 2026 |  Rohit KhannaD | Stock | Sell | $15,001 - $50,000 | $203.43 | $189.90 | -6.7% | -3.8% | |
Dec 18, 2025 |  Gilbert CisnerosD | Stock | Buy | $1,001 - $15,000 | $179.35 | $186.83 | +4.2% | +1.6% | |
Dec 8, 2025 |  Julia LetlowR | Stock | Buy | $1,001 - $15,000 | $180.68 | $188.36 | +4.3% | +3.1% | |
Nov 19, 2025 | Gilbert CisnerosD | Stock | Buy | $1,001 - $15,000 | $179.82 | $181.23 | +0.8% | -2.2% | |
Oct 31, 2025 |  Lisa McClainR | Stock | Sell | $1,001 - $15,000 | $82.40 | $92.72 | +12.5% | +12.3% | |
Oct 30, 2025 | Lisa McClainR | Stock | Sell | $1,001 - $15,000 | $82.34 | $92.72 | +12.6% | +12.1% | |
Oct 30, 2025 | Lisa McClainR | Stock | Buy | $1,001 - $15,000 | $82.34 | $92.72 | +12.6% | +12.1% | |
Oct 21, 2025 | Gilbert CisnerosD | Stock | Buy | $1,001 - $15,000 | $83.22 | $88.68 | +6.6% | +9.4% | |
Sep 23, 2025 |  Valerie HoyleD | Stock | Sell | $1,001 - $15,000 | $150.37 | $165.08 | +9.8% | +8.5% | |
Jul 22, 2025 | Lisa McClainR | Stock | Buy | $1,001 - $15,000 | $69.99 | $80.46 | +15.0% | +13.9% | |
Jun 17, 2025 | Lisa McClainR | Stock | Sell | $1,001 - $15,000 | $70.48 | $68.78 | -2.4% | -7.8% | |
Jun 9, 2025 | Lisa McClainR | Stock | Buy | $1,001 - $15,000 | $72.51 | $70.33 | -3.0% | -7.4% | |
Apr 21, 2025 |  Bruce WestermanR | Stock | Sell | $1,001 - $15,000 | $66.44 | $69.20 | +4.2% | -9.3% | |
Mar 12, 2025 | Rohit KhannaD | Option | Buy | $1,001 - $15,000 | $148.55 | $130.31 | -12.3% | -8.1% | |
Mar 3, 2025 | Bruce WestermanR | Stock | Buy | $1,001 - $15,000 | $149.59 | $141.96 | -5.1% | -2.1% | |
Oct 29, 2024 | Valerie HoyleD | Stock | Buy | $1,001 - $15,000 | $73.65 | $65.80 | -10.7% | -13.6% |
Recent News
FDA Approval For AbbVie/AstraZeneca's Combination Treatment Could Set New Standard For Slow Growing Blood Cancer
Benzinga-Invalid Date
Viatris: Deep-Value Pharma With Emerging Growth Catalysts And Strong Cash Generation
SeekingAlpha-Invalid Date
Roche's Genentech Wins FDA Approval For Venclexta Plus Acalabrutinib As First And Only All-Oral, Fixed-Duration Regimen For Previously Untreated Chronic Lymphocytic Leukemia Patients
Benzinga-Invalid Date
Daiichi Sankyo And AstraZeneca's ENHERTU Gains European Medicines Agency Validation For HER2 Positive Early Breast Cancer After Showing 53% Reduced Risk Of Disease Recurrence
Benzinga-Invalid Date
Top 3 Health Care Stocks That May Collapse This Quarter
Benzinga-Invalid Date